格力地产(600185) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥599,753,231.61, a decrease of 78.41% compared to the same period last year[3]. - The net profit attributable to shareholders for the third quarter was ¥58,552,855.24, down 65.83% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥55,790,841.72, reflecting a decline of 69.14% compared to the previous year[3]. - The net profit attributable to shareholders for the year-to-date period was ¥154,461,011.99, down 75.89% compared to the same period last year[3]. - The company's total revenue for the first three quarters of 2022 was approximately ¥2.75 billion, compared to ¥6.17 billion in the same period of 2021, indicating a decline[71]. - The net profit for the third quarter of 2022 was approximately ¥152.43 million, a decrease from ¥638.91 million in the same quarter of 2021[72]. - Total comprehensive income attributable to the parent company was CNY 170,217,150.32, a decrease of 73.98% compared to CNY 629,993,975.87 in the same period last year[74]. - Basic and diluted earnings per share were both CNY 0.08, down from CNY 0.35 year-over-year[74]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥360,905,580.42, a significant decrease of 86.52% year-on-year[3]. - Net cash flow from operating activities was CNY 360,905,580.42, a significant decline of 86.52% from CNY 2,677,712,648.05 in the previous year[77]. - The company reported a net increase in cash flow from operating activities of CNY 3,527,676,767.96, compared to CNY 7,141,008,311.69 in the previous year, reflecting a decrease of 50.54%[77]. - Cash inflow from investment activities totaled CNY 523,786,872.87, compared to CNY 68,233,308.94 in the same period last year, indicating a substantial increase[77]. - Net cash flow from financing activities was negative CNY 720,158,865.53, an improvement from negative CNY 4,134,492,391.95 in the previous year[78]. - Cash and cash equivalents at the end of the period were CNY 1,124,790,052.81, down from CNY 1,550,088,954.40, a decrease of 27.53%[78]. Assets and Liabilities - Total assets increased by 0.92% to 33,234,764,372.58 from 32,931,269,465.12[42]. - Current assets rose to 26,196,922,042.30, up from 25,558,408,671.64, indicating a growth of approximately 2.52%[42]. - Non-current assets decreased by 4.54% to 7,037,842,330.28 from 7,372,860,793.48[42]. - Total liabilities as of September 30, 2022, were approximately ¥24.08 billion, compared to ¥23.91 billion in the previous year[51]. - Total liabilities increased to CNY 24,076,567,538.21 from CNY 23,907,952,496.94, reflecting a growth of 0.71%[85]. - Long-term borrowings rose to CNY 9,258,143,373.47, up from CNY 8,099,103,977.98, indicating an increase of 14.29%[81]. Operating Costs and Expenses - The company's operating costs for the first three quarters of 2022 were approximately ¥2.83 billion, down from ¥5.44 billion in the same period of 2021[71]. - The company's research and development expenses for the third quarter of 2022 were approximately ¥2.60 million, slightly up from ¥2.34 million in the same quarter of 2021[71]. Corporate Developments - The company plans to actively promote the management of its subsidiary Tianlong Technology Co., Ltd. by Kewah Bioengineering Co., Ltd.[24]. - The company is currently undergoing a major asset restructuring, which is temporarily suspended pending further developments[24]. - The company has received court rulings that have lifted restrictions on its shareholder rights related to its 62% stake in Tianlong Technology[48]. - The company is in the process of negotiating a settlement regarding arbitration cases involving its associate company, Kehua Bio[48].